31 Dec 2018 07:00
31 December 2018
Byotrol plc
("Byotrol", the "Group" or the "Company")
GRANT OF OPTIONS
Byotrol plc, the AIM listed anti-microbial technology company, announces that on 28 December 2018 it granted a total of 3,000,000 options over the Company's ordinary shares of 0.25 pence each ("Options" and "Ordinary Shares" respectively) under the Company's existing Enterprise Management Incentive Scheme to a PDMR and to an employee of the Company.
Some of the Options are being granted to a PDMR of the Company ("PDMR Options") and are detailed below:
| Position | No. of New Options Granted | No. of Options held post grant | Shareholding in existing Ordinary Shares in the Company
|
Richard Hayman | MD, Medimark Scientific Ltd | 2,000,000 | 2,000,000 | 8,080,235 |
| (PDMR) |
|
|
|
The Options, all of which are exercisable at 2 pence per Ordinary Share over a five year period, vest on varying dates and vest in 5 tranches subject to certain share price performance targets and other performance metrics. The Options expire on 28 June 2024.
Following the grant of the 3,000,000 Options, there will be 39,248,250 Options in issue representing 9.1% per cent. of the Company's issued share capital.
Enquiries:
Byotrol plc 01925 742 000
David Traynor - Chief Executive
finnCap Ltd 020 7220 0500
Geoff Nash / Kate Bannatyne - Corporate Finance
Richard Chambers - ECM
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.
Our patented suite of technologies deliver powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.
Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to www.byotrol.co.uk
Accordingly, the Company makes the following notification in accordance with the EU Market Abuse Regulation (No 596/2014):
| Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Richard Hayman |
| Reason for the Notification | |
a) | Position/status | MD, Medimark Scientific Limited |
b) | Initial notification/Amendment | Initial |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Byotrol Plc |
b) | LEI | 213800AJMTSTIPA59A34 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument
Identification code | ordinary shares of 0.25p each ("Ordinary Shares")
GB00B0999995 |
b) | Nature of the transaction | Award of Options over Ordinary Shares |
c) | Price(s) and volume(s) | Volume - 2,000,000 Exercise Price - 2 pence |
d) | Aggregated information: | See 4c) above |
e) | Date of the transaction | 28 December 2018 |
f) | Place of the transaction | Outside of a trading venue |
BYOT.L (BYOT)